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Staphylococcus aureus is both a colonizer of humans
and a cause of severe invasive infections. Although
the genetic basis for phenotype switching from colo-
nizing to invasive has received significant study,
knowledge of host factors that antagonize the switch
is limited. We show that VLDL and LDL lipopro-
teins interfere with this switch by antagonizing the
S. aureus agr quorum-sensing system that upregu-
lates genes required for invasive infection. Themech-
anism of antagonism entails binding of the major
structural protein of these lipoproteins, apolipopro-
tein B, to an S. aureus autoinducing pheromone, pre-
venting attachment of this pheromone to the bacteria
and subsequent signaling through its receptor, AgrC.
Mice deficient in plasma apolipoprotein B, either ge-
netically or pharmacologically, are more susceptible
to invasiveagr+bacterial infection,butnot to infection
withanagrdeletionmutant. Therefore, apolipoprotein
B at homeostatic levels in blood is an essential innate
defense effector against invasive S. aureus infection.
INTRODUCTION
The host response to bacteria that both colonize their hosts and
cause invasive, lethal infection is complex and requires selective
host defense effectors that limit invasive infection while tolerating
colonization at epithelial surfaces. Staphylococcus aureus
colonizes 20%–30% of the population persistently and another
50%–60% transiently, and, while the number of invasive
infections is increasing, especially those caused by methicillin-
resistant bacteria (MRSA)-like strains of the USA300 PFGE type
(Klevens et al., 2007), they still reflect a small percentage of colo-
nized individuals. This suggests that the majority of normal human
hosts, even if colonized, have intact barriers to invasive infection.
Moreover, it suggests that failures in these barriers may increase
the susceptibility to invasive infection. Therefore, we postulated
that specific elements of acute inflammation are likely to discrim-
inate between these two outcomes of S. aureus-host interaction.
Virulence factor expression by S. aureus is regulated by a
complex set of signals that are integrated to induce transcriptionCell Hostof genes required for survival within distinct niches in response to
sensing the host environment (Cheung et al., 2004; Torres et al.,
2007; Yarwood et al., 2002). agr is a four-gene operon present in
the majority of S. aureus clinical isolates that controls, in part,
a change in phenotype from adhesive and colonizing to tissue
damaging and invasive (George and Muir, 2007). It encodes
a quorum-sensing system driven from the transcription of two
promoters, P2 and P3; one codes for synthesis and secretion
of an autoinducing cyclic thiolactone peptide (AIP) and a
two-component regulatory pathway, and the other generates
in response to AIP a regulatory RNA transcript, RNAIII, that is
the effector of the operon. Four different AIPs are produced by
S. aureus types that differ in amino acid composition and length
but retain the thiolactone structure (George and Muir, 2007) with
type 1 AIP predominating in clinical isolates. After RNAIII is pro-
duced, it downregulates expression of surface adhesins while
upregulating expression of secreted toxins, proteases, lipase,
and metabolic pathways (George and Muir, 2007). We postu-
lated that innate immunity and, specifically, elements of acute
inflammation would regulate this phenotypic change and thus
contribute to maintaining the host-pathogen balance toward
a noninvasive outcome. During acute inflammation, increases
in vascular permeability result in plasma leakage into the injured
tissue (Bucci et al., 2005). Because AIP interaction with its recep-
tor, AgrC, involves, in part, recognition of the thiolactone ring by
a hydrophobic pocket within the receptor (Wright et al., 2004;
George and Muir, 2007; Jensen et al., 2008), we hypothesized
that lipoproteins secreted by the liver and present in plasma
that extravasates to acutely infected tissue would antagonize
AIP signaling through AgrC. Here, we show that apolipoprotein
B, the major structural protein of very low-density lipoproteins
(VLDL) and low-density lipoproteins (LDL), sequesters AIP1
and thus inhibits agr signaling and limits invasive infection
caused by both laboratory strains and MRSA USA 300 isolates.
RESULTS
Serum Low-Density Lipoproteins Antagonize
Pheromone AIP1 Signaling
We hypothesized that constituents of plasma, specifically
lipoproteins, could provide a check against quorum-sensing-
dependent virulence at sites of S. aureus infection by interfering
with the interaction of AIP with an essential hydrophobic pocket& Microbe 4, 555–566, December 11, 2008 ª2008 Elsevier Inc. 555
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Host Lipoproteins Antagonize Quorum SensingFigure 1. Serum Lipoproteins Antagonize agr Signaling
(A) agr:P3 promoter activation by 100 nM AIP 1 is inhibited in S. aureus (ALC 1743 with agr:P3-gfp, 2 3 107/ml) during 3 hr of culture with either broth or the
indicated dilutions of pooled human serum (PHS) as compared to lipoprotein deficient sera (LPDS). Magnitude of promoter activation was measured as
fluorescence induction (mean channel of fluorescence [MCF]). (Inset) Log CFU indicated that bacterial growth was equivalent under both conditions. Data are
represented as the mean ± SEM; n = 3 performed in duplicate.
(B) Effect of VLDL, LDL, or HDL at equivalent cholesterol concentration (0.4 mM) on 100 nM AIP1-induced agr:P3 activation during 3 hr of culture of ALC1743. Data
are represented as the mean ± SEM; n = 3 performed in duplicate.
(C) Relative quantification of RNA III transcript to 16 s RNA produced by USA300 clinical isolate UAMS 1378 cultured at 2 3 107/ml with 100 nM AIP1 with or
without 2 mg/ml VLDL for 1 hr. Data are represented as the mean ± SEM; n = 4 performed in triplicate.
(D) Dose-dependent inhibition of AIP1-induced agr:P3 activation by purified apolipoprotein B, but not other serum lipoproteins. Concentrations tested: apoB,
2–8 mg/ml (4–16 nM); apoA-I, 4–8 mg/ml (143–288 nM); apoC-1, 4–8 mg/ml (0.61–1.2 mM); and apoE, 4–8 mg/ml (117–234 nM).
(E) Goat IgG anti-apoB (5 mg/ml) versus control goat IgG reversed VLDL (5 mg/ml) and purified apoB (5 mg/ml) inhibition of AIP1-induced agr:P3 activation in
ALC1743. Data are represented as the mean ± SEM; n = 3 performed in duplicate.
(F) mAB C1.4 IgG1 anti-apoB (5 mg/ml) versus control mouse IgG1 reversed VLDL (5 mg/ml) inhibition of 100 nM AIP1-induced relative RNA III transcript produced
by USA300 clinical isolate LAC cultured at 2 3 107/ml for 1 hr. Data are represented as the mean ± SEM; n = 3 performed in duplicate.within its cognate receptor AgrC (Wright et al., 2004; Jensen
et al., 2008). Using a reporter strain where activation of the agr
P3 promoter drives expression of GFP (Rothfork et al., 2004),
synthetic AIP1 (100 nM) induced activation of the P3 promoter
optimally at 3 hr, and inclusion of dilutions of pooled human556 Cell Host & Microbe 4, 555–566, December 11, 2008 ª2008 Elsserum (PHS), as compared to lipoprotein-deficient pooled
human serum (LPDS), inhibited its function (Figure 1A), indicating
that serum lipoproteins can antagonize AIP1 signaling without
affecting bacterial growth (CFU) (Figure 1A, inset). Inclusion of
mouse, chicken, rabbit, or bovine sera also inhibited activationevier Inc.
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Host Lipoproteins Antagonize Quorum Sensing(data not shown). Culture of the bacteria in 10% PHS also
inhibited spontaneous P3 promoter activation during longer
culture times as compared to 10% LPDS without affecting
bacterial growth, indicating that serum lipoproteins can inhibit
endogenous AIP function (Figure S1A available online). Purified
human VLDL and LDL particles, as compared to high-density
lipoproteins (HDL) at equivalent cholesterol concentrations
(0.4 mM), significantly antagonized AIP1-induced P3 activation
(Figure 1B) also with no effect on bacterial CFU (data not shown).
Moreover, inclusion of VLDL significantly inhibited AIP1-induced
RNAIII transcript production relative to 16S RNA as measured by
qRT-PCR in the USA300 clinical isolate UAMS1378 (Figure 1C).
These data indicate that the lowest density lipoproteins secreted
by the liver into blood significantly and specifically antagonize
AIP1-dependent signaling in both laboratory strains and clinical
isolates associated with invasive infections.
Apolipoprotein B Is Sufficient and Necessary
to Antagonize AIP1 Signaling and Secretion
of Virulence Factors Required for Invasive Infection
Serum lipoproteins are complex particles composed of a neutral
core containing triglycerides and cholesterol esters covered by
an amphipathic monolayer of phospholipids and unesterified
cholesterol. The protein, apo, components bind to the surface
of the particles and are either restricted to particular lipoproteins
or freely exchangeable across lipoprotein categories (Olofsson
and Boren, 2005). We asked whether the major structural nonex-
changeable apo protein, apolipoprotein B, of VLDL and LDL was
able to inhibit AIP1-induced agrP3 promoter activation. ApoB in-
hibited in a dose-dependent fashion at concentrations (8 mg/ml)
less than normal serum values (80 mg/ml) (Figure 1D) with no
effect on bacterial CFU (data not shown). Other apolipoproteins,
apoA-1, apoC-1, and apoE, had no effect, indicating that AIP
antagonism is not a general property of lipid-binding proteins
(Figure 1E). Treatment of either VLDL or apoB with antibody
against apoB, but not control IgG, reversed the ability of both
to inhibit AIP1-induced P3 activation (Figure 1E), indicating that
any associated lipids were not sufficient for antagonism and
that antigenic epitopes of apoB were essential. Moreover,
VLDL inhibition of AIP1-induced RNAIII transcript production in
the USA300 strain LAC (also AIP1) was reversed by a monoclonal
antibody against an epitope in the amino terminal domain of
apoB (mAb C1.4), but not by an isotype control antibody
(Figure 1F). Additionally, treatment of PHS with mAb C1.4 versus
an isotype control increased spontaneous P3 promoter activa-
tion in ALC1743 and RNAIII transcript production in LAC during
culture in the presence of 10% PHS (Figures S1B and S1C). Con-
sistent with these data indicating apoB in the control of agr:P3
promoter activation, liposomes composed of various phospho-
lipids and cholesterol had no effect on AIP signaling (Figure S2A).
Inclusion of the triglyceride tributyrin partially reduced AIP sig-
naling (Figure S2B), but it required concentrations approximately
five times higher than normally observed in serum. These data
demonstrate that apolipoprotein B is both sufficient and neces-
sary for inhibition of AIP1 signaling in both laboratory strains and
important clinical isolates.
Activation of agr contributes to the regulation of at least
70 genes, including 23 known virulence factors like a hemolysin
and lipase. We determined the effect of VLDL and purified apoBCell Hostonahemolysin (hla) promoter activation and secretion ofahemo-
lysin and lipase by multiple laboratory strains and clinical
isolates, including MRSA isolates of the USA 300 and 400
PFGE types that currently contribute to invasive human infection
(Klevens et al., 2007). Apolipoprotein B inhibited AIP1-induced
hla promoter activation (Figure S3A) and both AIP1-induced
(Figure S3B) and spontaneous (Figure S3C) secretion of a hemo-
lysin by both a laboratory strain (SH1000) and multiple USA 300
isolates (USA 300 3757, UAMS 1378, and LAC). In addition,
apoB and VLDL inhibited AIP1-induced lipase secretion in all
strains tested, including USA300 isolates (Figures S3D and
S3E). Moreover, apoB inhibited type 3 AIP signaling in a USA
400 strain, suggesting that apolipoprotein B inhibition may not
be limited to the type I peptide (Figure S3B).
Apolipoprotein B and Its Associated Lipid Particles
Antagonize agr Signaling by Inhibiting AIP1 Binding
to Bacteria and Sequestering It for Uptake
by Macrophages
ApoB-containing lipoproteins could antagonize activation of the
agr P3 promoter either by blocking AIP1 binding to the bacteria
or by inhibiting signaling consequent to AIP1 binding. To deter-
mine whether apoB could block recognition of AIP1 by AgrC,
we evaluated binding of AIP1 synthesized with an FITC tag in
the amino terminus to wild-type bacteria. Specific FITC-AIP1
binding was inhibited by 50% by an equal concentration of
soluble native AIP1, indicating that FITC-AIP1 and native AIP1
compete equally for binding (Figure 2A). While both VLDL and
purified apoB inhibited FITC-AIP1 binding to both RN6390 and
the clinical USA300 isolate, LAC (Figures 2A and 2C), apoA-1
did not. Neither VLDL nor apoB inhibited binding of FITC-labeled
IgG to the bacteria, indicating that lipoprotein-mediated
inhibition was specific to AIP and not the FITC tag (Figure 2B).
These data indicate that apoB-containing lipoproteins antago-
nize agr signaling by blocking AIP1 binding.
ApoB-containing lipoproteins could inhibit AIP1 binding either
by occupying its binding site in its cognate receptor or by
sequestering AIP1 away from the bacteria. Unlike LDL binding
to Group A Streptococci (Han et al., 2006), we did not detect di-
rect binding of LDL to the S. aureus strains we studied under the
conditions we examined (data not shown). We used surface
plasmon resonance (SPR) to compare direct binding of purified
apoB (10 nM) to either native AIP1 or linear AIP1 immobilized
at equivalent concentrations via a biotin at the amino terminus
to a streptavidin-coated chip (Figure 2D). This binding was
dose dependent (Figure S4A) and specific to apoB as equal mo-
lar concentrations of apoC1 or apoA1 did not result in detectable
binding as measured as resonance units (Figure 2D). Injection of
apoB over biologically inactive linear AIP1 did not result in
detectable binding even though equivalent amounts of the cyclic
and linear forms of AIP1 were bound to the chips (Figure 2D), in-
dicating that an intact thiolactone ring is required for interaction.
Therefore, we determined whether other native AIPs and AIPs
modified to limit their biologic activity while retaining the thiolac-
tone ring could compete against immobilized AIP1 to prevent
apoB binding. As predicted, soluble native AIP1, but not linear
AIP1, prevented apoB binding (Figure S4B). Native AIP2 and
AIP4 were equivalent if not better than soluble native AIP1 and
caused significant (p < 0.001) inhibition of apoB binding to& Microbe 4, 555–566, December 11, 2008 ª2008 Elsevier Inc. 557
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oxidants to create a methionine sulfoxide variant that lacks
biologic activity (Rothfork et al., 2004) and AIP3 synthesized
with a tyrosine in the amino terminus that is nonfunctional (Otto
et al., 1998) prevented apoB binding to immobilized AIP1 (Fig-
ure S4B), indicating that chemical modifications that result in
loss of function but retain the thiolactone ring permit interaction
with apoB. A control cyclic peptide made by disulfide crosslink-
ing had no effect (Figure S4B). In addition, apoB bound to immo-
bilized AIP1 could be removed by washing with 0.5% SDS and
the chip reused to demonstrate new apoB binding, indicating
that the interaction of apoB with AIP1 retained the native confor-
mation of AIP1 required for apoB recognition. This suggests that
the interaction of the two is reversible. These data indicate
that apoB-containing lipoproteins antagonize agr signaling by
binding AIP through recognition of the thiolactone ring and
preventing AIP ligation of the AgrC receptor.
Because macrophages express scavenger receptors that
bind apoB-containing LDL modified either by oxidation or acet-
ylation (Moore and Freeman, 2006), we postulated that lipopro-
tein sequestering of AIP1 could contribute to host defense by
facilitating uptake and destruction of AIP1 by macrophages.
LDL modified by acetylation was equivalent to native lipopro-
teins in antagonizing AIP1 signaling, and the inhibition was
reversed by an mAb to an amino-terminal epitope in apoB, but
Figure 2. Apolipoprotein B and Its Associ-
ated Lipid Particles Inhibit AIP Binding to
S. aureus and Interact with AIP by Surface
Plasmon Resonance
(A) S. aureus (RN 6390, 23 107/ml) was incubated
with 1 mM FITC-AIP1 alone (vehicle control) or in
combination with potential inhibitors including
1 mM native AIP1, VLDL (2 mg/ml), apoB (8 mg/ml),
or apoA-1 (8 mg/ml) at 37C for 3 hr. Specific
binding was measured by flow cytometry. Data
are represented as the mean ± SEM; n = 4.
(B) One micromolar FITC-IgG binding to S. aureus
RN6390 was not inhibited by VLDL or apoB. Data
are represented as the mean ± SEM; n = 3.
(C) S. aureus (USA300 LAC, 2 3 107/ml) was
incubated with 1 mM FITC-AIP1 in vehicle control
or in combination with VLDL (2 mg/ml) or apoB
(8 mg/ml) at 37C for 3 hr. Specific binding was
measured by flow cytometry. Data are represented
as the mean ± SEM; n = 2 performed in duplicate.
(D) Biacore X100 analysis in resonance units (RU)
of the interaction of 10 nM apoB, apoC1, or
apoA1 with either cyclic biotin-AIP1 or linear
biotin-AIP1 immobilized on streptavidin chips after
60 s of contact time followed by 60 s of dissocia-
tion time at a flow rate of 10 ml/min. Data are
represented as mean ± SEM; n = 3–5.
not by an mAb of the same isotype
against a carboxy-terminal epitope,
indicating that chemical modification of
LDL does not affect apoB antagonism
of AIP1 (Figure 3A). To exclude the possi-
bility of a direct inhibitory effect of AcLDL
on the bacteria, we incubated bacteria
with AIP1 and AcLDL for 3 hr, washed, and then incubated
with either broth or AIP1. These bacteria were fully able to dem-
onstrate spontaneous activation of the agr:P3 promoter as well
as respond to AIP (Figure 3B). To examine scavenger receptor
uptake of AIP1, murine RAW264 macrophages were incubated
on ice with acetylated LDL with a red fluorescent label (DiI-
Ac-LDL) and then with FITC-AIP1. After increasing the tempera-
ture to 37C, the percentage of colocalization of the red and
green fluorescence was evaluated by confocal microscopy (Fig-
ure 3C). At 10 min, 60% of the FITC-AIP1 colocalized with
Ac-LDL (Figure 3D). Controls included using unlabeled Ac-LDL
that demonstrated only green fluorescence, using DiI-Ac-LDL
without FITC-AIP1 to demonstrate only red fluorescence, and
using FITC avidin to demonstrate that the colocalization was
specific to AIP1 and not to the FITC tag. To demonstrate that
this colocalization was dependent on apoB, an mAb that
reversed apoB inhibition of AIP1 signaling (mAb C1.4, Figure 3A)
significantly inhibited colocalization of FITC-AIP1 with AcLDL
(Figure 3D). Complexes of AcLDL and FITC-AIP1 that were
dialyzed prior to addition to the cells demonstrated equivalent
levels of colocalization (Figure 3D). Similar results were obtained
with primary murine bone marrow macrophages (data not
shown). These data demonstrate that modified LDL can specif-
ically bind and sequester AIP1 for uptake and destruction by
macrophages present at the site of infection.558 Cell Host & Microbe 4, 555–566, December 11, 2008 ª2008 Elsevier Inc.
Cell Host & Microbe
Host Lipoproteins Antagonize Quorum SensingMice with Genetically Low Levels of Plasma
Apolipoprotein B Are More Susceptible to agr+ versus
Dagr S. aureus Infection
Synthesis of apolipoprotein B by hepatocytes initiates assembly
of VLDL particles that after secretion into blood are metabolized
into LDL particles that are removed for degradation by the LDL
receptor. The absolute blood level of apoB is determined by
both liver VLDL secretion and the uptake and degradation of
apoB-containing particles by the LDL receptor (Shelness and
Sellers, 2001). If apolipoprotein B is essential for defense against
quorum-sensing-dependent invasive infection, then mice with
low blood levels of apoB should be more susceptible to agr+
infection, but not infection with an agr deletion mutant. To test
this, we used an air pouch model of infection to compare the
responses of wild-type mice and mice with diminished blood
levels of apoB due to overexpression of the LDL receptor as
a consequence of genetic deletion of PCSK9, a subtilisin family
proprotein convertase that downregulates LDL receptor
Figure 3. Interaction of AIP with Modified LDL and Uptake by Macrophage Scavenger Receptors
(A) LDL modified by acetylation (5 mg/ml) inhibits AIP1-induced agr:P3 promoter activation, and the inhibition is reversed by an mAb to an N-terminal epitope of
apoB (mAb C1.4) (5 mg/ml), but not by an mAb against a C-terminal epitope (mAb 4C11) (5 mg/ml). Data are represented as the mean ± SEM; n = 3 performed in
duplicate.
(B) Reversibility of AIP1-induced agr:P3 promoter activation inhibited by modified LDL. Reporter bacteria incubated with 50 nM AIP1 and 5 mg/ml AcLDL for 3 hr
first and then washed and incubated subsequently with either broth or 500 nM AIP1 demonstrated both spontaneous and AIP1-induced agr:P3 promoter
activation. Data are represented as the mean ± SEM; n = 2 performed in duplicate.
(C) RAW264 murine macrophages were incubated first with mixtures of fluorescently labeled and unlabeled AcLDL on ice and then with FITC-AIP1 for 10 or 30 min
at 37C. Fixed cells were imaged by confocal microscopy. (First row) RAW cells incubated with unlabeled AcLDL (10 mg/ml) and then with FITC-AIP1 (green
fluorophore, 1 mM). Confocal images show no bleed through to the red channel. (Second row) RAW cells incubated with DiI-AcLDL (red fluorophore, 1 mg/ml)
and unlabeled AcLDL (9 mg/ml). Confocal images show no bleed through to the green channel. (Third row) RAW cells incubated with DiI-AcLDL (1 mg/ml)
and unlabeled AcLDL (9 mg/ml) and then FITC-AIP1 (1 mM). Images show colocalization of LDL and AIP. (Fourth row) RAW cells incubated with DiI-AcLDL
(1 mg/ml) and unlabeled AcLDL (9 mg/ml) and then FITC-avidin (1 mM). The FITC tag does not colocalize with Ac-LDL.
(D) Percent colocalization of FITC-AIP1 with AcLDL determined at both early (mean ± SEM; n = 38 cells) and later time points (mean ± SEM; n = 30 cells) using
Slidebook as described in Experimental Procedures. As controls, AcLDL was treated with mAb anti-apoB (clone C1.4) (5 mg/ml) before interacting with FITC-AIP1,
and the percent colocalization (mean ± SEM; n = 50 cells) was significantly reduced (p < 0.001). Also, dialyzing the AcLDL/FITC-AIP1 complex prior to incubation
with the macrophages resulted in equivalent colocation (mean ± SEM; n = 36 cells).Cell Host & Microbe 4, 555–566, December 11, 2008 ª2008 Elsevier Inc. 559
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Host Lipoproteins Antagonize Quorum Sensingexpression (Horton et al., 2007). These mice are viable, develop
normally, and are otherwise healthy (Rashid et al., 2005), unlike
apoB knockout mice that have multiple development problems
and early embryonic lethality (Farese et al., 1995). Pouches
generated by the subcutaneous injection of air become lined
with epithelium over 6 days and have been used to study
in vivo bacterial biofilm formation (Yoshikawa et al., 2004)
(Figure 1E), and we have shown that agr contributes to invasive
infection in this model in a dose-dependent manner (Rothfork
et al., 2003, 2004). Infection of Pcsk9/ mice (black bars) with
early exponential phase (i.e., nonfluorescent) agr P3:gfp reporter
bacteria at a dose handled easily by wild-type mice (white bars)
resulted in significantly greater morbidity, bacterial burden at the
site of infection and spleen, agr P3 promoter activation by the
bacteria at the site of infection, inflammatory cytokine (MIP-2)
concentration at the site of infection, and epidermal biofilm for-
mation and invasion into the dermis (Figures 4A–4D). In contrast,
infection with an equivalent CFU of an isogenic agr deletion
mutant resulted in no significant differences between wild-type
and Pcsk9 knockout mice (Figures 4A, 4B, and 4D). Importantly,
Pcsk9 deficiency at this challenge dose revealed significant dif-
ferences in morbidity, bacterial burden, and MIP-2 concentration
between agr+- and agr- infected mice (black bars, Figures 4A,
4B, and 4D), demonstrating its requirement to control contribu-
tions of agr to pathogenesis. Microscopic evaluation of the
pouch tissue from either strain of mice infected with the agr
deletion mutant and stained with anti-S. aureus linked to a red
fluorophore revealed minimal numbers of detectable bacteria
(data not shown). In contrast, confocal microscopy of pouch
tissue from the Pcsk9/ mice infected with either early (Fig-
ure 4F, right panel) or midexponential phase (Figure 4G right
panel) agr+(ALC1743) bacteria, as compared to wild-type mice
(Figures 4F and 4G, left panels), had significantly greater bacte-
rial density in the epidermis (measure of biofilm formation) and
significantly greater numbers of GFP-expressing bacteria (either
green or yellow), indicating that they had undergone quorum
sensing (quantification shown in Figures 4F and 4G graphs).
Moreover, the bacterial density, the magnitude of in vivo quorum
sensing, and invasion beyond the epidermis into the dermis and
underlying muscle correlated with the morbidity score of the
mice, and in all cases, these were significantly greater for the
apoB-deficient mice (Figures 4F and 4G, right panels and graph).
These data indicate that the reduction of apoB-containing
lipoproteins in the plasma of otherwise healthy mice makes them
significantly more susceptible to quorum-sensing-dependent
invasive infection, but not to infection by nonquorum-sensing
S. aureus.
VLDL and LDL Represent an Additional Barrier beyond
theNADPHPhagocyteOxidase forControl of agr+ versus
Dagr S. aureus Infection
The phagocyte NADPH oxidase (phox) plays multiple roles in
host defense against S. aureus infection (Quinn et al., 2006;
Kobayashi et al., 2004). We previously demonstrated that its
contribution to oxidant inactivation of AIP1 signaling contributes,
in part, to control of quorum-sensing-dependent infection (Roth-
fork et al., 2004). To determine that apoB-containing lipoproteins
represent a separate and distinct barrier against invasive
quorum-sensing-dependent infection, we used pharmacologic560 Cell Host & Microbe 4, 555–566, December 11, 2008 ª2008 Elstreatment to lower plasma apoB levels of mice genetically defi-
cient in phox (gp91phox/) (Pollock et al., 1995). Phox-deficient
mice treated with a drug 4APP that inhibits low-density lipopro-
tein secretion by the liver (Mounkes et al., 2001) were signifi-
cantly more susceptible to MRSA USA300 LAC agr+ infection
than vehicle control-treated mice. They had significantly greater
morbidity, weight loss, and bacterial burden at the site of infec-
tion and systemically (Figures 5A–5C). In contrast, 4APP treat-
ment of these mice did not increase susceptibility to infection
with the agr deletion mutant (Figures 5A–5C). Importantly, as
with Pcsk9 deficiency, 4APP treatment revealed significant
differences in morbidity, weight loss, and bacterial burden
between agr+ and Dagr infected mice (Figures 5A–5C). Micro-
scopic evaluation of the pouch tissue stained with anti-S. aureus
(red fluorescence) revealed significantly greater bacterial density
in the epidermis of 4APP-treated mice infected with agr+ bacte-
ria (Figures 5D and 5E). In contrast, 4APP treatment had no
significant effect on the pouch tissue of mice infected with the
agr deletion mutant. Importantly, 4APP-treated mice infected
with wild-type LAC had significantly increased density of bacte-
ria that had invaded deep into the dermis and muscle underlying
the air pouch with bacteria surrounding the muscle fibers (Fig-
ures 5F and 5G). Equivalent results were obtained with the
agr+ and agr RN6390 strains (Figure S5) and with the USA300
UAMS1378 strain and its agr deletion mutant (UAMS1540)
(Figure S6). These data indicate that secreted low-density lipo-
protein represents an innate barrier against quorum-sensing-
dependent invasive S. aureus infection caused by agr type 1
laboratory strains or MRSA clinical isolates associated with
invasive skin infections.
DISCUSSION
Staphylococcus aureus, a colonizer of mucosal and epithelial
surfaces and a pathogen capable of invading beyond these
barriers, uses a complex network to regulate gene transcription
essential for survival at these different sites. One mechanism by
which the innate immune system could provide defense against
invasive infection is not just by providing effectors that lead to
bacterial killing but also by providing effectors that target viru-
lence systems that permit survival beyond the epithelial barrier.
In this work, we demonstrate that the major structural protein
of VLDL and LDL, apolipoprotein B, antagonizes the agr quo-
rum-sensing operon and selectively limits invasive infection of
agr group 1 bacteria to epidermal spaces without any direct bac-
tericidal effect. Importantly, we were able to show a role for these
lipoproteins in control of invasive MRSA USA300 infections that
are increasing in number and severity (Klevens et al., 2007).
These data extend our previous observation that reactive oxygen
and nitrogen intermediates generated by the phagocyte oxidase
inactivate the type 1 autoinducing pheromone of the agr operon
(Rothfork et al., 2004), demonstrating that multiple effectors of
innate immunity provide defense by targeting virulence gene
regulation by S. aureus. However, in contrast to the current
work, the phagocyte oxidase provides defense by multiple
mechanisms, including both intracellular and extracellular killing
of this pathogen (Ahluwalia et al., 2004; Quinn et al., 2006; Fuchs
et al., 2007). Another example of a mammalian defense effector
that targets quorum-sensing signaling without affecting bacterialevier Inc.
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the acyl homoserine lactone pheromones of Pseudomonas
aeruginosa (Ozer et al., 2005; Yang et al., 2005).
Apolipoprotein B is a large (4536 amino acids) amphipathic
lipid-binding protein with a pentapartite structure composed of
a globular amino terminus, two domains of b pleated sheets,
and two a-helical domains that span the entire surface of the
lipoprotein particle (Segrest et al., 2001; Olofsson and Boren,
2005). While it never exists in blood independently of the associ-
ated lipid particle, our data indicate that this structural protein is
Figure 4. Effect of agr on S. aureus Infection of Apolipoprotein-Deficient Pcsk9/ Mice as Compared to Wild-Type Mice
Air pouches generated on the backs of B6 3 129 wild-type or Pcsk9/ mice (n = 8 for each group) were infected with either 3.5 3 107 nonfluorescent early
exponential phase S. aureus agr:P3-gfp ALC 1743 (agr+) or 3.2 3 107 agr:P3-gfp ALC1753 (agr). At 28 hr postinfection, the following parameters were
determined and represented as the mean ± SEM:
(A) Morbidity was scored on a 0–14 point scale.
(B) Bacterial burden (Log CFU) of pouch lavage and spleen.
(C) Quantification of agr:P3-gfp promoter activation by flow cytometry of bacteria isolated from the pouch lavage.
(D) MIP-2, a murine inflammatory cytokine, was measured in the pouch lavage.
(E) H & E stain of the basal section of pouch tissue demonstrating bacteria at the surface of the lumen, the epidermis and dermis with infiltrating leukocytes, and
the skeletal muscle.
(F) Representative pouch tissue from B6 3 129 mice (left panel) versus Pcsk9/ mice (right panel) infected with early exponential phase S. aureus (agr:P3-gfp
ALC1743). Pouch tissue was fixed and sectioned, and sagittal sections were stained with anti-S. aureus antibody (red fluorophore). Quorum-sensing S. aureus
were visible by production of GFP in the pouch. Graph represents the relative density of both total and GFP+ bacteria in the epidermis from at least 19
representative areas.
(G) Representative pouch tissue from B6 3 129 mice (left panel) versus Pcsk9/ mice (right panel) infected with midexponential phase S. aureus (agr:P3-gfp
ALC1743) and stained with anti-S. aureus (red fluorophore) demonstrated significantly more quorum sensing, biofilm formation, and invasion into the dermis
at 28 hr postinfection in Pcsk9/ mice. Graph represents the relative density of both total and GFP+ bacteria in the epidermis from at least 19 representative
areas. *p < 0.02; **p < 0.005. L = lumen, D = dermis, E = epidermis, and MS = morbidity score. Arrows indicate point of greatest penetration by quorum-sensing
bacteria. Scale bar, 50 mm.Cell Host & Microbe 4, 555–566, December 11, 2008 ª2008 Elsevier Inc. 561
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Host Lipoproteins Antagonize Quorum SensingFigure 5. Effect of agr onUSA300 (LAC)S. aureus Infection of NADPHOxidase Knockout (gp91phox/) Mice Treatedwith 4APP to Inhibit Liver
Secretion of Lipoproteins
Mice were treated with 100 ml of 5 mg/ml 4APP or vehicle control (0.025 M phosphate buffer) (n = 4 for each group) i.p. 48 and 24 hr prior to infection of air
pouches with either 2.5 3 107 CFU of USA300 LAC or LACD agr. At 25 hr postinfection, the following parameters were determined and the data represented
as the mean ± SEM:
(A) Morbidity was scored on a 0–14 point scale.
(B) Weight loss in grams.
(C) Bacterial burden (Log CFU) in pouch lavage and spleen.
(D) Representative pouch tissue from control and 4APP-treated mice stained with anti-S. aureus antibody (red fluorophore), demonstrating biofilm-like
aggregates (arrowhead) and increased numbers of bacteria in the epidermis in 4APP-treated mice infected with wild-type LAC. Scale bar, 50 mm.562 Cell Host & Microbe 4, 555–566, December 11, 2008 ª2008 Elsevier Inc.
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Host Lipoproteins Antagonize Quorum Sensingresponsible for VLDL and LDL inhibition of AIP1 binding and sig-
naling because (1) the individual lipid constituents of the lipopro-
tein particles at normal serum concentration did not inhibit AIP1
function, (2) antibody against apoB reversed VLDL, LDL, and
AcLDL inhibition, (3) apoB purified away from its associated lipid
by ether extraction and size chromatography was sufficient for
inhibition, and (4) apoB bound directly to immobilized native
AIP1, but not linear AIP1, by SPR. While direct binding of LDL
via apoB to prions (Safar et al., 2006) and group A streptococci
(Han et al., 2006) has been demonstrated, whether this contrib-
utes to host defense and/or to virulence is unknown. We did not
detect direct binding of LDL to the strains we studied. Therefore,
we believe that the mechanism of antagonism involves seques-
tering of AIP1 by apoB within the lipoprotein particle. While the
domain or site involved is presently not known, a monoclonal
antibody to an epitope in the amino terminus reversed apoB
interaction with AIP1, suggesting that the amino-terminal
domain that initiates lipoprotein assembly in the liver may be
involved. In addition, analysis of the SPR kinetic data revealed
that either a one-to-one or a two-site interaction model could ex-
plain our results. Therefore, isolation of the domain or domains
involved will be required for definitive data on the affinity of
binding and the relevant stoichiometry. Moreover, because
alterations in the lipid composition of VLDL and LDL are known
to alter the conformation of apoB (Wang et al., 2000) and apoB
within VLDL appeared more potent than purified apoB in our
assays, the conformation of apoB as modified by associated
lipid may contribute to AIP antagonism.
While the majority of our data were demonstrated with apoB
interaction with AIP1 that predominates in clinical isolates, incu-
bation of AIP2 and AIP4 with apoB prevented its binding to solid
phase AIP1 and apoB inhibited AIP3-induced hemolysin produc-
tion, indicating that apoB may be involved in regulating quorum
sensing in all four S. aureus types. Because all four AIPs have
different amino acid sequences but retain the thiolactone ring
(George and Muir, 2007) and apoB did not bind to linear solid
phase AIP1, we suspect that antagonism requires recognition
of a thiolactone-dependent conformation that is essential for
binding to the cognate AgrC receptor (Wright et al., 2004; Jensen
et al., 2008). Once bound via apoB to the lipoprotein particle, AIP
could be degraded following uptake by macrophage scavenger
receptors (Moore and Freeman, 2006). Intriguingly, mice defi-
cient in one of these, CD 36, are more susceptible to S. aureus
infection (Hoebe et al., 2005; Stuart et al., 2005), and whether
this involves impaired control of quorum sensing is a point of
speculation. Finally, because neat lipoprotein-deficient serum
retained some ability to inhibit AIP1 signaling, other in vivo antag-
onists of AIP function are likely to contribute to control of quorum
sensing.
The agr operon is only one of many global regulators that act
subsequent to specific sensing to alter expression of various
virulence factors by S. aureus (Cheung et al., 2004; Torres
et al., 2007). However, the majority of clinical isolates are agr+,Cell Hostand agr deletion mutants are attenuated particularly in skin infec-
tion models (Rothfork et al., 2003, 2004; Wright et al., 2005),
suggesting that, even though it shares targets with other regula-
tors, it has a unique role in the pathogenesis of S. aureus infec-
tions. In our model, Dagr bacteria are confined to the 100 mm
of the epidermis at the base of the air pouch, indicating that
agr-mediated repression of adhesins that retain bacteria in the
epidermis and upregulation of tissue-degrading enzymes are
required for bacterial invasion into the dermis and possibly
across the endothelium into the blood stream. In addition, our
data demonstrate that the NADPH oxidase of phagocytes and
VLDL and LDL in plasma play nonredundant roles in limiting
AIP1-dependent activation of agr at this site. However, this has
not been confirmed for all AIP types. In acute inflammation,
leukocyte emigration across the endothelium into injured tissue
occurs early with subsequent vascular leakage and plasma
extravasation (Bucci et al., 2005) and, thus, would provide tem-
poral control of agr activation. Moreover, sites of acute infection
can become rapidly hypoxic (Peyssonnaux et al., 2005), which
would limit oxidase control of AIP function, and extravasated
lipoprotein-mediated inhibition would predominate. If this barrier
fails, the bacteria would gain access via the blood stream to
virtually every tissue site. In the vasculature, agr may have little
if any role (Yarwood et al., 2002), and recent data indicate that
hemoglobin released from lysing erythrocytes or present within
reticuloendothelial tissues actively suppresses production of
the agr effector, RNAIII (Schlievert et al., 2007), possibly through
the newly described heme sensor system HssRS (Torres et al.,
2007), leading to reduced toxin production and attenuation.
This could benefit the bacterium by permitting re-expression of
adhesins required for attachment to endothelium to aid in
escape from the neutrophil-rich blood stream into other tissues.
In the blood stream, quorum sensing would be limited to bacteria
able to escape antagonism or repression of agr either by clump-
ing to prevent inactivation of the AIP (Rothfork et al., 2003) or by
internalization into cells. Thus, multiple cycles of agr activation
and repression regulated by both the pathogen and the host
may occur during pathogenesis of this infection.
Lipoprotein particle levels and their constituents are exten-
sively altered by acute inflammation and infection (Gabay and
Kushner, 1999). In fact, hypocholesterolemia has been consis-
tently correlated with worse outcomes in critically ill patients
(Windler et al., 1994; Gordon et al., 2001; Gui et al., 1996; Marik,
2006). The molecular mechanisms underlying this are poorly
understood, but measurements of various lipid parameters in
patients with severe sepsis or septic shock indicate that apoB
lipoprotein levels can be very low (Kitchens et al., 2003; Vermont
et al., 2005; van Leeuwen et al., 2003). Because our data indicate
that homeostatic levels of apoB-expressing lipoproteins are
required to provide adequate defense against quorum-sensing
invasive S. aureus infections, clinical scenarios that result in
extremely low apoB-containing lipoproteins may increase the
risk of invasive S. aureus infection, including MRSA infections.(E) Quantification of bacterial density in the epidermis of pouch tissue from control and 4APP-treated mice from at least 22 representative areas.
(F) Representative muscle and deep dermis tissue from control and 4APP-treated mice infected with wild-type LAC stained with anti-S. aureus antibody
(red fluorophore), demonstrating bacteria surrounding muscle bundles (arrows). Scale bar, 20 mM.
(G) Quantification of bacterial density in muscle and deep dermis tissue of pouches from control and 4APP-treated mice from at least 25 representative areas of
530 mM2. *p < 0.05, **p < 0.01, ***p < 0.001. L = lumen, D = dermis, and E = epidermis.& Microbe 4, 555–566, December 11, 2008 ª2008 Elsevier Inc. 563
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have been performed on patients with limited versus invasive
S. aureus infection. Moreover, expression of truncated variants
(Shelness et al., 2003) and/or known polymorphisms in apoB
(Chiodini et al., 2003) may affect its ability to antagonize agr
signaling depending on the site or domain within apoB that binds
AIP. Therefore, variations in either the quality or amount of apoB
in plasma may alter innate defense against quorum sensing by
this pathogen.
Our data do not address whether excess apoB-containing
lipoproteins as would occur in hyperlipidemia can prevent infec-
tion. In fact, high circulating levels of oxidized LDL contribute to
impaired Th1 immunity and increased susceptibility to experi-
mental infection with some pathogens (Shamshiev et al., 2007),
suggesting, in conjunction with the present work, that dyslipide-
mia alters multiple parameters required for host defense (Marik,
2006). While the majority of work published to date on the role of
lipoproteins in host defense has focused on neutralization of
lipopolysaccharide (Kitchens et al., 2003), our work defines a




Synthetic AIPs were generated as follows and stored in DMSO at 80C:
cyclic AIP1 (YSTC[/M]DFIM[/C]), FITC-AIP1, and biotin-AIP1 were synthe-
sized by Commonwealth Biotechnologies, Inc., Richmond, VA, using a
described method (Otto et al., 1998). Cyclic AIP 2 (GVNAC[/F]SSLF[/C]),
AIP4 (YSTC[/M]YFIM[/C]), and AIP3 antagonist (YINC[/L]DFLL[/C])
were generated as described (Otto et al., 1998). A disulfide linked cyclic
peptide, C(/C)LLRMKSAC(/C), was used as a control. Linear AIP1 and
biotin-AIP1 were generated by alkaline hydrolysis and neutralization, and a
methionine sulfoxide variant of AIP1 was produced by incubation with hydro-
gen peroxide and myeloperoxidase as described (Rothfork et al., 2004). Both
were checked for loss of functional activity and structure by mass spectros-
copy as described (Rothfork et al., 2004). The following reagents and sera
were obtained as indicated: purified human VLDL, LDL, HDL, apoB, apoA1,
apoC1, and apoE (US Biological, Swampscott, MA); purified Ac-LDL,
DiI-Ac-LDL, and DiI-LDL (Biomedical Technologies Inc., Stoughton, MA);
pooled human serum, lipoprotein-deficient serum, chicken serum, tributyrin,
4-aminopyrazolo-(3,4-D) pyrimide (4APP), and a liposome preparation reagent
containing cholesterol, phosphatidyl choline, and stearylamine (Sigma-
Aldrich, St. Louis, MO); cholesterol and phosphatidylcholine (Avanti Polar
Lipids); polyclonal goat IgG anti-human apolipoprotein B 100 (R&D Systems,
Minneapolis, MN); monoclonal murine IgG1 anti-human apoB C1.4 (Santa
Cruz Biotechnology, Santa Cruz, CA); and monoclonal murine IgG1
anti-human apoB 4C11 (Biodesign International, Saco, ME).
Bacterial Strains and Culture
The bacterial strains used in this study were as follows: ALC 1743 (agr group 1
RN6390 containing reporter agr:P3-gfp), ALC 1740 (RN6390 containing re-
porter hla-gfp), ALC 1753 (RN6911 agr deletion mutant of RN6390 containing
reporter agr:P3-gfp), RN6390, SH1000 (s B corrected RN6390), and ALC 1225
geh (strain 8325-4 with geh deletion mutant with reduced lipase secretion)
(Kupferwasser et al., 2003; Rothfork et al., 2004). USA300 strain UAMS1378
and its agr deletion mutant UAMS1540 were provided by Dr. Mark Smeltzer
(University of Arkansas), and USA300 strain LAC and its agr deletion mutant
were prepared as described (Wang et al., 2007). Clinical isolates of CA-
MRSA agr group 1 USA 300 (NM 300) and agr group 3 USA 400 (NM 400)
were provided by Dr. Steve Young, Department of Pathology, University of
New Mexico, and USA 300 strain FPR 3757 was provided by Dr. Francoise
Perdreau-Remington, UCSF. To generate synchronized early exponential
phase, nonfluorescent bacteria, frozen stocks were cultured either in Colum-564 Cell Host & Microbe 4, 555–566, December 11, 2008 ª2008 Elsbia broth or Trypticase soy broth (TSB) (Becton Dickinson, Franklin Lakes,
NJ) as described (Rothfork et al., 2003). CFU were determined after washing
and sonication to disrupt clumps by plating serial dilutions on blood agar
(Becton Dickinson, Franklin Lakes, NJ).
Bacterial Promoter Activation
Early exponential phase, nonfluorescent reporter bacteria (ALC1743 and
ALC1740) (2 3 107/ml) were incubated in 1 ml TSB in polystyrene tubes with
shaking (200 rpm, 37C) for the indicated times with either broth or vehicle con-
trol, synthetic AIP1 (100 nM), or AIP1 treated with antagonists including sera,
lipoprotein particles, apo protein, or other lipids. For inhibition of spontaneous
activation of agr:P3, AlC1743 was incubated with 90% TSB with either 10%
PHS, 10% LPDS, 10% PHS preincubated on ice for 30 min with 10 mg/ml
murine IgG1, or 10% PHS preincubated on ice for 30 min with mAB C1.4 for
the times indicated in the figure legend. After incubation, bacteria were
washed by centrifugation at 3000 rpm for 4 min at 4C in PBS with 0.1% Triton
X-100, sonicated, cultured for CFU, and then fixed with 1% paraformaldehyde
containing 25 mM CaCl2 for analysis by flow cytometry (FACSCalibur, Becton
Dickinson, Franklin Lakes, NJ). Promoter activation was demonstrated as
fluorescence induction and measured as the mean channel fluorescence
(MCF) of GFP-positive bacteria.
Quantitative RT-PCR
Early exponential phase USA300 strains UAMS1378 or LAC (23 107/ml) were
cultured as above with either broth, 100 nM AIP1, or AIP1 with 2 mg/ml VLDL for
1 hr. For strain LAC, the VLDL was preincubated with either IgG1 anti-apoB
(mAb C1.4) or isotype control (both 5 mg/ml) on ice for 30 min prior to addition
to the assay. In addition, LAC was incubated with either 10% PHS treated with
murine IgG1 or with 10% PHS treated with mAb C1.4 anti-apoB and cultured
as indicated in the figure legends. RNAIII was quantified relative to 16S RNA
using a probe-based assay as described with minor modifications (Sawires
and Gresham, 2008) as detailed in the Supplemental Data.
Surface Plasmon Resonance
Surface plasmon resonance was performed with the Biacore X100 (Biacore
Life Sciences, GE Healthcare) to analyze the interaction of apoproteins with
immobilized AIP1. N-terminal biotinylated AIP1 in both the native and linear
conformation were immobilized on streptavidin sensor chips according to
the manufacturer’s protocol. The details of the conditions of running the
assays and their evaluation are given in the Supplemental Data.
Additional experimental details of virulence factor assays, FITC-AIP1
binding to the bacteria, macrophage colocalization experiments, and the air
pouch model of infection and its evaluation are given in the Supplemental Data.
Statistical Evaluation
Data are displayed as the mean ± SEM. In vitro data were analyzed by the
Student’s t test and the in vivo results by the Mann-Whitney U test for nonpara-
metrics using StatView for Macintosh.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures
and six figures and can be found with this article online at http://www.
cellhostandmicrobe.com/supplemental/S1931-3128(08)00308-9.
ACKNOWLEDGMENTS
This work was supported by the Department of Veterans Affairs (HDG) and NIH
grants AI-064926 (H.D.G.), AI 47441 (A.L.C.), and AI 37142 (A.L.C.). We thank
Martha Gutierrez for excellent technical assistance; Drs. Francoise Perdreau-
Remington, Frank DeLeo, and Mark Smeltzer for providing bacterial strains;
Dr. Jake Lusis for sera and cell lysates from PON knockout mice; and
Drs. Esteban Roberts, Vojo Deretic, and Richard Larson for access to critical
equipment. Images in this paper were generated in the University of New
Mexico Cancer Center Fluorescence Microscopy Facility, supported as
detailed at http://hsc.unm.edu/crtc/microscopy/facility.html.evier Inc.
Cell Host & Microbe
Host Lipoproteins Antagonize Quorum SensingReceived: December 22, 2007
Revised: August 8, 2008
Accepted: October 6, 2008
Published: December 10, 2008
REFERENCES
Ahluwalia, J., Tinker, A., Clapp, L.H., Duchen, M.R., Abramov, A.Y., Pope, S.,
Nobles, M., and Segal, A.W. (2004). The large-conductance Ca2+-activated
K+ channel is essential for innate immunity. Nature 427, 853–858.
Bucci, M., Roviezzo, F., Posadas, I., Yu, J., Parente, L., Sessa, W.C., Ignarro,
L.J., and Cirino, G. (2005). Endothelial nitric oxide synthase activation is critical
for vascular leakage during acute inflammation in vivo. Proc. Natl. Acad. Sci.
USA 102, 904–908.
Cheung, A.L., Bayer, A.S., Zhang, G., Gresham, H., and Xiong, Y.Q. (2004).
Regulation of virulence determinants in vitro and in vivo in Staphylococcus
aureus. FEMS Immunol. Med. Microbiol. 40, 1–9.
Chiodini, B.D., Barlera, S., Franzosi, M.G., Beceiro, V.L., Introna, M., and Toq-
noni, G. (2003). APO B gene polymorphisms and coronary artery disease:
a meta-analysis. Atherosclerosis 167, 355–366.
Farese, R.V., Jr., Ruland, S.L., Flynn, L.M., Stokowski, R.P., and Young, S.G.
(1995). Knockout of the mouse apolipoprotein B gene results in embryonic
lethality in homozygotes and protection against diet-induced hypercholester-
olemia in heterozygotes. Proc. Natl. Acad. Sci. USA 92, 1774–1778.
Fuchs, T.A., Abed, U., Goosmann, C., Hurwitz, R., Schulze, I., Wahn, V.,
Weinrauch, Y., Brinkmann, V., and Zychlinsky, A. (2007). Novel cell death
program leads to neutrophil extracellular traps. J. Cell Biol. 176, 231–241.
Gabay, C., and Kushner, I. (1999). Acute-phase proteins and other systemic
responses to inflammation. N. Engl. J. Med. 340, 448–454.
George, E.A., and Muir, T.W. (2007). Molecular mechanisms of agr quorum
sensing in virulent staphylococci. Chembiochem 8, 847–855.
Gordon, B.R., Parker, T.S., Levine, D.M., Saal, S.D., Wang, J.C., Sloan, B.J.,
Barrie, P.S., and Rubin, A.L. (2001). Relationship of hypolipidemia to cytokine
concentrations and outcomes in critically ill surgical patients. Crit. Care Med.
29, 1563–1568.
Gui, D., Spada, P., De Gaetano, A., and Pacelli, F. (1996). Hypocholesterole-
mia and risk of death in the critically ill surgical patient. Intensive Care Med.
22, 790–794.
Han, R., Caswell, C.C., Lukomska, E., Keene, D.R., Pawlowski, M., Bujnicki,
J.M., Kim, J.K., and Lukomski, S. (2006). Binding of the low-density lipoprotein
by streptococcal collagen-like protein Scl1 of Streptococcus pyogenes. Mol.
Microbiol. 61, 351–367.
Hoebe, K., Georgel, P., Rutschmann, S., Du, X., Mudd, S., Crozat, K., Sovath,
S., Shamel, L., Hartung, T., Zahringer, U., and Beutler, B. (2005). CD36 is a
sensor of diacylglycerides. Nature 433, 523–527.
Horton, J.D., Cohen, J.C., and Hobbs, H.H. (2007). Molecular biology of
PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32, 71–77.
Jensen, R.O., Winzer, K., Clarke, S.R., Chan, W.C., and Williams, P. (2008).
Differential recognition of Staphylococcus aureus quorum-sensing signals
depends on both extracellular loops 1 and 2 of the transmembrane sensor
AgrC. J. Mol. Biol. 381, 300–309.
Kitchens, R.L., Thompson, P.A., Munford, R.S., and O’Keefe, G.E. (2003).
Acute inflammation and infection maintain circulating phospholipid levels
and enhance lipopolysaccharide binding to plasma lipoproteins. J. Lipid
Res. 44, 2339–2348.
Klevens, R.M., Morrison, M.A., Nadle, J., Petit, S., Gershman, K., Ray, S.,
Harrison, L.H., Lynfield, R., Dumyati, G., Townes, J.M., et al. (2007). Invasive
methicillin-resistant Staphylococcus aureus infections in the United States.
JAMA 298, 1763–1771.
Kobayashi, S.D., Voyich, J.M., Braughton, K.R., Whitney, A.R., Nauseef, W.M.,
Malech, H.L., and DeLeo, F.R. (2004). Gene expression profiling provides
insight into the pathophysiology of chronic granulomatous disease.
J. Immunol. 172, 636–643.Cell HostKupferwasser, L.I., Yeaman, M.R., Nast, C.C., Kupferwasser, D., Xiong, Y.Q.,
Palma, M., Cheung, A.L., and Bayer, A.S. (2003). Salicylic acid attenuates
virulence in endovascular infections by targeting global regulatory pathways
in Staphylococcus aureus. J. Clin. Invest. 112, 222–233.
Marik, P.E. (2006). Dyslipidemia in the critically ill. Crit. Care Clin. 22, 151–159.
Moore, K.J., and Freeman, M.W. (2006). Scavenger receptors in atherosclero-
sis: beyond lipid uptake. Arterioscler. Thromb. Vasc. Biol. 26, 1702–1711.
Mounkes, L.C., Zhong, W., de Silva, H.V., Handumrongkul, C., Desai, B., Tse,
E., Taylor, J.M., and Debs, R.J. (2001). Evaluation of the role of lipoprotein me-
tabolism genes in systemic cationic liposome-mediated gene transfer in vivo.
Hum. Gene Ther. 12, 1939–1954.
Olofsson, S.-O., and Boren, J. (2005). Apolipoprotein B: a clinically important
apolipoprotein which assembles atherogenic lipoproteins and promotes the
development of atherosclerosis. J. Intern. Med. 258, 395–410.
Otto, M., Sussmuth, R., Jung, G., and Gotz, F. (1998). Structure of the phero-
mone peptide of the Staphylococcus epidermidis agr system. FEBS Lett. 424,
89–94.
Ozer, E.A., Pezzulo, A., Shih, D.M., Chun, C., Furlong, C., Lusis, A.J.,
Greenberg, E.P., and Zabner, J. (2005). Human and murine paraoxonase
1 are host modulators of Pseudomonas aeruginosa quorum-sensing. FEMS
Microbiol. Lett. 253, 29–37.
Peyssonnaux, C., Datta, V., Cramer, T., Doedens, A., Theodorakis, E., Gallo,
R., Hurtado-Ziola, N., Nizet, V., and Johnson, R. (2005). HIF-1 alpha expres-
sion regulates the bactericidal capacity of phagocytes. J. Clin. Invest. 115,
1806–1815.
Pollock, J.D., Williams, D.A., Gifford, M.A., Li, L.L., Du, X., Fisherman, J., Orkin,
S.H., Doerschuk, C.M., and Dinauer, M.C. (1995). Mouse model of X-linked
chronic granulomatous disease, an inherited defect in phagocyte superoxide
production. Nat. Genet. 9, 202–209.
Quinn, M.T., Ammons, M.C., and Deleo, F.R. (2006). The expanding role of
NADPH oxidases in health and disease: no longer just agents of death and
destruction. Clin. Sci. (Lond.) 111, 1–20.
Rashid, S., Curtis, D.E., Garuti, R., Anderson, N.N., Bashmakov, Y., Ho, Y.K.,
Hammer, R.E., Moon, Y.A., and Horton, J.D. (2005). Decreased plasma
cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl.
Acad. Sci. USA 102, 5374–5379.
Rothfork, J.M., Dessus-Babus, S., Van Wamel, W.J., Cheung, A.L., and
Gresham, H.D. (2003). Fibrinogen depletion attenuates Staphyloccocus
aureus infection by preventing density-dependent virulence gene
up-regulation. J. Immunol. 171, 5389–5395.
Rothfork, J.M., Timmins, G.S., Harris, M.N., Chen, X., Lusis, A.J., Otto, M.,
Cheung, A.L., and Gresham, H.D. (2004). Inactivation of a bacterial virulence
pheromone by phagocyte-derived oxidants: new role for the NADPH oxidase
in host defense. Proc. Natl. Acad. Sci. USA 101, 13867–13872.
Safar, J.G., Wille, H., Geschwind, M.D., Deering, C., Latawiec, D., Serban, A.,
King, D.J., Legname, G., Weisgraber, K.H., Mahley, R.W., et al. (2006). Human
prions and plasma lipoproteins. Proc. Natl. Acad. Sci. USA 103, 11312–11317.
Sawires, Y., and Gresham, H. (2008). Improved probe-based assay for the
quantification of Staphylococcus aureus virulence regulator, RNAIII, both
in vitro and in vivo. J. Rapid Meth. and Automation in Microbiol. 16, 140–153.
Schlievert, P.M., Case, L.C., Nemeth, K.A., Davis, C.C., Sun, Y., Qin, W.,
Wang, F., Brosnahan, A.J., Mleziva, J.A., Peterson, M.L., and Jones, B.E.
(2007). alpha and beta chains of hemoglobin inhibit production of Staphylo-
coccus aureus exotoxins. Biochemistry 46, 14349–14358.
Segrest, J.P., Jones, M.K., De Loof, H., and Dashti, N. (2001). Structure of
apolipoprotein B-100 in low density lipoproteins. J. Lipid Res. 42, 1346–1367.
Shamshiev, A.T., Ampenberger, F., Ernst, B., Rohrer, L., Marsland, B.J., and
Kopf, M. (2007). Dyslipidemia inhibits Toll-like receptor-induced activation of
CD8 alpha-negative dendritic cells and protective Th1 type immunity. J.
Exp. Med. 204, 441–452.
Shelness, G.S., and Sellers, J.A. (2001). Very-low-density lipoprotein
assembly and secretion. Curr. Opin. Lipidol. 12, 151–157.& Microbe 4, 555–566, December 11, 2008 ª2008 Elsevier Inc. 565
Cell Host & Microbe
Host Lipoproteins Antagonize Quorum SensingShelness, G.S., Hou, L., Ledford, A.S., Parks, J.S., and Weinberg, R.B. (2003).
Identification of the lipoprotein initiating domain of apolipoprotein B. J. Biol.
Chem. 278, 44702–44707.
Stuart, L.M., Deng, J., Silver, J.M., Takahashi, K., Tseng, A.A., Hennessy, E.J.,
Ezekowitz, R.A., and Moore, K.J. (2005). Response to Staphylococcus aureus
requires CD36-mediated phagocytosis triggered by the COOH-terminal
cytoplasmic domain. J. Cell Biol. 170, 477–485.
Torres, V.J., Stauff, D.L., Pishchany, G., Bezbradica, J.S., Gordy, L.E.,
Iturregui, J., Anderson, K.L., Dunman, P.M., Joyce, S., and Skaar, E.P.
(2007). A Staphyloccus aureus regulatory system that responds to host
heme and modulates virulence. Cell Host Microbe 1, 109–119.
van Leeuwen, H.J., Heezius, E.C., Dallinga, G.M., van Strijp, J.A., Verhoef, J.,
and van Kessel, K.P. (2003). Lipoprotein metabolism in patients with severe
sepsis. Crit. Care Med. 31, 1359–1366.
Vermont, C.L., den Brinker, M., Kakeci, N., de Kleijn, E.D., de Rijke, Y.B.,
Joosten, K.F., de Groot, R., and Hazelzet, J.A. (2005). Serum lipids and
disease severity in children with severe meningococcal sepsis. Crit. Care
Med. 33, 1610–1615.
Wang, X., Pease, R., Bertinato, J., and Milne, R.W. (2000). Well-defined
regions of apolipoprotein B-100 undergo conformational change during its
intravascular metabolism. Arterioscler. Thromb. Vasc. Biol. 20, 1301–1308.
Wang, R., Braughton, K.R., Kretschmer, D., Bach, T.H., Queck, S.Y., Li, M.,
Kennedy, A.D., Dorward, D.W., Klebanoff, S.J., Peschel, A., et al. (2007).566 Cell Host & Microbe 4, 555–566, December 11, 2008 ª2008 ElsIdentification of novel cytolytic peptides as key virulence determinants for
community-associated MRSA. Nat. Med. 12, 1510–1514.
Windler, E., Ewers-Grabow, U., Thiery, J., Walli, A., Seidel, D., and Greten, H.
(1994). The prognostic value of hypocholesterolemia in hospitalized patients.
Clin. Investig. 72, 939–943.
Wright, J.S., III, Lyon, G.J., George, E.A., Muir, T.W., and Novick, R.P. (2004).
Hydrophobic interactions drive ligand-receptor recognition for activation and
inhibition of staphylococcal quorum sensing. Proc. Natl. Acad. Sci. USA
101, 16168–16173.
Wright, J.S., III, Jin, R., and Novick, R.P. (2005). Transient interference with
staphylococcal quorum sensing blocks abscess formation. Proc. Natl. Acad.
Sci. USA 102, 1691–1696.
Yang, F., Wang, L.H., Wang, J., Dong, Y.H., Hu, J.Y., and Zhang, L.H. (2005).
Quorum quenching enzyme activity is widely conserved in the sera of mamma-
lian species. FEBS Lett. 579, 3713–3717.
Yarwood, J.M., McCormick, J.K., Paustian, M.L., Kapur, V., and Schlievert,
P.M. (2002). Repression of the Staphylococcus aureus accessory gene
regulator in serum and in vivo. J. Bacteriol. 184, 1095–1101.
Yoshikawa, Y., Morikawa, K., Nonaka, M., and Torii, I. (2004). Effect of
arbekacin on a methicillin-resistant Staphylococcus aureus-induced biofilm
in a rat model. J. Infect. Chemother. 10, 268–273.evier Inc.
